GEP20053420B - Sustained Release Ranolanolazine Formulation - Google Patents

Sustained Release Ranolanolazine Formulation

Info

Publication number
GEP20053420B
GEP20053420B GE4322A GEAP1999004322A GEP20053420B GE P20053420 B GEP20053420 B GE P20053420B GE 4322 A GE4322 A GE 4322A GE AP1999004322 A GEAP1999004322 A GE AP1999004322A GE P20053420 B GEP20053420 B GE P20053420B
Authority
GE
Georgia
Prior art keywords
ranolanolazine
formulation
sustained release
ranolazine
essence
Prior art date
Application number
GE4322A
Other languages
English (en)
Inventor
Andrew A Wolff
Fiona Baker
John Richard Langridge
Original Assignee
Cv Therapeutics Inc
Syntex Usa Llk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20053420(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc, Syntex Usa Llk filed Critical Cv Therapeutics Inc
Publication of GEP20053420B publication Critical patent/GEP20053420B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
GE4322A 1998-09-10 1999-09-09 Sustained Release Ranolanolazine Formulation GEP20053420B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
GEP20053420B true GEP20053420B (en) 2005-01-25

Family

ID=26796494

Family Applications (1)

Application Number Title Priority Date Filing Date
GE4322A GEP20053420B (en) 1998-09-10 1999-09-09 Sustained Release Ranolanolazine Formulation

Country Status (33)

Country Link
US (14) US6303607B1 (en:Method)
EP (3) EP1527779A1 (en:Method)
JP (2) JP3745621B2 (en:Method)
KR (1) KR100475759B1 (en:Method)
CN (2) CN1211086C (en:Method)
AR (3) AR022085A1 (en:Method)
AT (2) ATE285774T1 (en:Method)
AU (4) AU744071B2 (en:Method)
BR (2) BR9913626A (en:Method)
CA (2) CA2343376C (en:Method)
CY (1) CY2008020I1 (en:Method)
CZ (2) CZ301341B6 (en:Method)
DE (3) DE69922964T2 (en:Method)
DK (2) DK1096937T3 (en:Method)
ES (2) ES2234302T3 (en:Method)
FR (1) FR09C0001I2 (en:Method)
GE (1) GEP20053420B (en:Method)
HK (1) HK1044284B (en:Method)
HU (2) HU224215B1 (en:Method)
IL (6) IL141892A0 (en:Method)
LU (1) LU91504I2 (en:Method)
MX (2) MXPA01002598A (en:Method)
NL (1) NL300371I2 (en:Method)
NO (4) NO320986B1 (en:Method)
NZ (2) NZ510384A (en:Method)
PL (3) PL196263B1 (en:Method)
PT (2) PT1109558E (en:Method)
RU (2) RU2214233C2 (en:Method)
SI (2) SI1096937T1 (en:Method)
TR (2) TR200101262T2 (en:Method)
TW (1) TWI241911B (en:Method)
UA (2) UA67793C2 (en:Method)
WO (2) WO2000013686A2 (en:Method)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
EP2033633A3 (en) 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
ES2523873T3 (es) 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2616845A1 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007108362A1 (ja) * 2006-03-17 2007-09-27 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518181A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US7943620B2 (en) * 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
EP2155697B1 (en) * 2007-06-13 2012-11-28 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
US20090203707A1 (en) * 2008-02-06 2009-08-13 Sridharan Rajamani Methods for treating pain
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
BR112012006433A2 (pt) 2009-09-25 2016-04-19 Lupin Ltd composição de libertação sustentada de ranolazina
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
NO3175985T3 (en:Method) 2011-07-01 2018-04-28
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
EP1096937B9 (en) 2007-02-28
US6864258B2 (en) 2005-03-08
JP2006096757A (ja) 2006-04-13
AR053440A2 (es) 2007-05-09
IL141893A0 (en) 2002-03-10
AU760435B2 (en) 2003-05-15
AU6142599A (en) 2000-03-27
WO2000013687A2 (en) 2000-03-16
US20060217397A1 (en) 2006-09-28
JP3745621B2 (ja) 2006-02-15
US20050153982A1 (en) 2005-07-14
HK1040060A1 (en) 2002-05-24
IL141892A0 (en) 2002-03-10
CA2343376C (en) 2007-01-09
HUP0103844A2 (hu) 2002-04-29
US6562826B1 (en) 2003-05-13
US20020090396A1 (en) 2002-07-11
ES2234302T3 (es) 2005-06-16
CY2008020I2 (el) 2010-07-28
IL141892A (en) 2006-08-20
DE69922964T2 (de) 2005-12-08
CZ301341B6 (cs) 2010-01-20
US20040097514A1 (en) 2004-05-20
CZ2001879A3 (cs) 2001-08-15
HK1044284A1 (en) 2002-10-18
US20020004506A1 (en) 2002-01-10
PL196668B1 (pl) 2008-01-31
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
CA2342390A1 (en) 2000-03-16
NL300371I1 (nl) 2009-02-02
US20060147521A1 (en) 2006-07-06
IL175371A0 (en) 2006-09-05
WO2000013687A3 (en) 2000-06-29
RU2207856C2 (ru) 2003-07-10
BR9913626A (pt) 2001-12-04
NO2009005I2 (en:Method) 2010-06-28
US20030099705A1 (en) 2003-05-29
NZ510384A (en) 2002-10-25
LU91504I2 (fr) 2009-02-03
MXPA01002598A (es) 2002-04-08
CA2343376A1 (en) 2000-03-16
NO20011192L (no) 2001-04-30
TR200101261T2 (tr) 2002-05-21
US6620814B2 (en) 2003-09-16
NL300371I2 (nl) 2009-10-01
CN1211086C (zh) 2005-07-20
PT1096937E (pt) 2005-04-29
PL196263B1 (pl) 2007-12-31
US20040029890A1 (en) 2004-02-12
PL348249A1 (en) 2002-05-20
BR9913553A (pt) 2001-10-23
CZ301375B6 (cs) 2010-02-03
EP1109558A2 (en) 2001-06-27
AU6036499A (en) 2000-03-27
US20050059667A1 (en) 2005-03-17
EP1096937A2 (en) 2001-05-09
US20030166659A1 (en) 2003-09-04
MXPA01002599A (es) 2005-02-17
US6369062B1 (en) 2002-04-09
US20030100566A1 (en) 2003-05-29
CN1354665A (zh) 2002-06-19
IL141893A (en) 2008-08-07
TR200101262T2 (tr) 2001-12-21
US6852724B2 (en) 2005-02-08
NO20011191L (no) 2001-04-30
CY2008020I1 (el) 2010-07-28
IL180864A0 (en) 2007-07-04
NZ510386A (en) 2003-08-29
DE69901570T2 (de) 2003-01-09
HUP0103844A3 (en) 2002-11-28
AU2008207707A1 (en) 2008-09-25
US6303607B1 (en) 2001-10-16
US6503911B2 (en) 2003-01-07
WO2000013686A3 (en) 2000-07-06
EP1096937B1 (en) 2004-12-29
PT1109558E (pt) 2002-10-31
DE122008000065I1 (de) 2009-04-09
CZ2001880A3 (cs) 2001-08-15
NO2009005I1 (no) 2009-03-16
JP2002524416A (ja) 2002-08-06
FR09C0001I1 (en:Method) 2009-02-27
US6525057B2 (en) 2003-02-25
ATE217794T1 (de) 2002-06-15
AU2008207703A1 (en) 2008-09-25
US6617328B2 (en) 2003-09-09
CA2342390C (en) 2006-08-29
SI1096937T1 (en) 2005-04-30
ATE285774T1 (de) 2005-01-15
NO20011191D0 (no) 2001-03-08
DK1109558T3 (da) 2002-08-26
NO319434B1 (no) 2005-08-15
FR09C0001I2 (en:Method) 2009-12-18
NO20054324L (no) 2001-04-30
AR022085A1 (es) 2002-09-04
HU224215B1 (hu) 2005-06-28
AR052921A1 (es) 2007-04-11
HUP0104088A3 (en) 2002-12-28
HK1044284B (zh) 2005-07-15
UA75027C2 (uk) 2006-03-15
KR100475759B1 (ko) 2005-03-10
CN1321088A (zh) 2001-11-07
HUP0104088A2 (hu) 2002-05-29
PL202207B1 (pl) 2009-06-30
NO320986B1 (no) 2006-02-20
ES2177346T3 (es) 2002-12-01
DE69922964D1 (de) 2005-02-03
SI1109558T1 (en) 2002-10-31
UA67793C2 (uk) 2004-07-15
RU2214233C2 (ru) 2003-10-20
AU744071B2 (en) 2002-02-14
NO20011192D0 (no) 2001-03-08
TWI241911B (en) 2005-10-21
EP1527779A1 (en) 2005-05-04
DE69901570D1 (de) 2002-06-27
KR20010089874A (ko) 2001-10-12
LU91504I9 (en:Method) 2019-01-02
CN1193757C (zh) 2005-03-23
EP1109558B1 (en) 2002-05-22
DK1096937T3 (da) 2005-05-09

Similar Documents

Publication Publication Date Title
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
GEP20032999B (en) 1-Heterocycle Substituted Diarylamines
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
ID28003A (id) Turunan-turunan adamantana
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
ES2161690T3 (es) Formulaciones farmaceuticas.
CA2311450A1 (en) Pharmaceutical aerosol compositions
IL122249A0 (en) Fluorocarbon pharmaceutical formulations and their preparation
AU8933391A (en) Medical drug formulation and delivery system
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
HUP9600256A2 (en) Substituted diphenyl-sulfonamide endothelin antagonists, pharmaceutical compositions containing the same and their medical uses
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
IL107653A0 (en) N,n-disubstituted arylcycloalkylamines their preparation and pharmaceutical compositions containing them
EP0448091A3 (en) Pharmaceutical composition containing slightly water-soluble drug
IL97475A0 (en) Glycinamide derivatives,their preparation,pharmaceutical compositions containing them,and their application
ZA978383B (en) Pharmaceutical compositions comprising amisulpride and therapeutic applications thereof.
AU5650894A (en) Tachyquinine antagonists, their preparation and use in pharmaceutical formulations
HUP9800631A3 (en) 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
GB9501286D0 (en) Pharmaceutical compositions and preparations thereof
HUP9801068A2 (hu) 1,2,3,4-Tetrahidro-2-naftil-amin-származékok, ezek előállítása és alkalmazása, valamint ilyen származékokat tartalmazó gyógyászati készítmények
GEP20012518B (en) Novel Erythromycin Derivatives, Method for Their Preparation and Their Use as Medicine